Deadline on Sept. 12th coming up in Lawsuit for Investors in Molecular Partners AG (NASDAQ: MOLN)

A deadline is coming up on September 12, 2022 in the lawsuit filed for certain investors of Molecular Partners AG (NASDAQ: MOLN).

Investors who purchased shares of Molecular Partners AG (NASDAQ: MOLN) have certain options and there are strict and short deadlines running. Deadline: September 12, 2022. NASDAQ: MOLN)stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges on behalf of purchasers of Molecular Partners AG (NASDAQ: MOLN) common shares, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff claims that the Offering Documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, The plaintiff alleges that between June 16, 2021 and April 26, 2022 the Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.

More specifically, the plaintiff claims that the the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose that: (i) ensovibep was less effective at treating COVID-19 than Defendants had led investors to believe; (ii) accordingly, the FDA was reasonably likely to require an additional Phase 3 study of ensovibep before granting the drug EUA; (iii) waning global rates of COVID-19 significantly reduced the Company's chances of securing EUA for ensovibep; (iv) as a product candidate, MP0310 was less attractive to Amgen than Defendants had led investors to believe; (v) accordingly, there was a significant likelihood that Amgen would return global rights of MP0310 to Molecular Partners; (vi) as a result of all the foregoing, the clinical and commercial prospects of ensovibep and MP0310 were overstated; and (vii) as a result, the Offering Documents and Defendants' public statements between June 16, 2021 and April 26, 2022 were materially false and/or misleading and failed to state information required to be stated therein.

Those who purchased shares of Molecular Partners AG (NASDAQ: MOLN) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.